US Signals More Joint Yen Intervention With Japan if Currency Volatility Continues 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
U.S. Treasury Joins Japan in Yen Intervention as Currency Nears 40-Year Lows 
Australia Job Ads Rise in July, Signaling Strong Labor Market Despite High Interest Rates 
Gold Price Holds Above $4,050 as Fed Rate Outlook, Middle East Tensions Keep Markets on Edge 
Japanese Yen Rallies as Intervention Hopes and BOJ Outlook Weigh on USD/JPY 
Iran Warns of Retaliation as Trump Threatens New Strikes, Oil Risks Intensify 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Asian Stocks Rise as AI Optimism Returns, Australia Hits Record High Ahead of RBI Decision 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Oil Prices Rebound as U.S.-Iran Talk Uncertainty Keeps Markets on Edge 
Gulf Shipping Traffic Steady as U.S.-Iran Talks Remain Uncertain 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Apple Restores Telegram to App Store After Content Policy Violation 
Japan Economy Minister Downplays Inflation Risks Despite BOJ Warning 
Gold Prices Rise as Trump Delays Iran Strike, Oil Slumps 
SK Holdings revealed its acquisition of a French drug-maker called Yposkesi this week. The third-largest conglomerate in South Korea made the purchase in its bid to strengthen its competitive power in the global market’s biotech sector.
Moreover, SK has acquired French drug manufacturer Yposkesi to expand into the rapidly growing contract manufacturing organization (CMO) business, the newly renamed holding company of SK Group said Wednesday.
SK completed the acquisition
The Korea Times reported that SK acquired 70% percent shares, and this includes management rights in the French company. The acquisition came four months after the South Korean company said it is in talks to purchase Yposkesi.
The price of the deal was not mentioned in the reports, so there is no clear figure how much SK shelled out for the acquisition. The deal has been completed, and Yposkesi will now be operated by SK Pharmteco, a CMO subsidiary owned by SK Inc. based in Sacramento.
"We are glad to advance into the gene therapy CMO business by investing in Yposkesi which has great capability and potential," Jang Dong Kyun, SK’s chief executive officer, said. "We will spare no efforts to help Yposkesi grow fast in the global market."
About Yposkesi
Yposkesi, the French cell, and gene therapy company, is also one of the largest Contract Development & Manufacturing Organizations (CDMO) in Europe. With the purchase of this company, SK will now be able to supply innovative drugs around the world through creating a contract manufacturing organization (CMO) business system, as per Aju Business Daily.
Yposkesi was launched in 2016 by AFM-Téléthon and by the SPI fund managed by Bpifrance. It is the first French firm to develop and produce gene and cell therapy products. The company’s goal is to create the first treatments available to patients then sell them for a fair price.
Meanwhile, this is SK Holding’s third acquisition deal in the global CMO industry as it aims to be one of the best players in the biotechnology industry. Its purchase of pharma and biotech companies shows its determination to rise above in the market for this field.
"SK plans to complete the value chain of its synthetic and biopharmaceutical CMO business in the U.S., Europe and Asia by 2025," SK’s head in bio investment center, Lee Dong Hoon, said. "We will foster SK Pharmteco as a global leading CMO that can supply synthetic, gene and cell therapy drugs to the global pharmaceutical market."
